Medtronic Plc
MDT
Market Cap$106.43B
Close$
Earnings Call Q4 2025
May 21, 2025 - AI Summary
Strong Q4 Performance: Medtronic reported Q4 revenue of $8.9 billion, growing 5.4% organically year-over-year. EPS rose 11% to $1.62, with the company achieving mid-single-digit revenue growth for 2.5 years consecutively, demonstrating the durability of its growth drivers.
Separation of Diabetes Business: Medtronic announced a planned spin-off of its Diabetes business into a standalone public company through an IPO and subsequent share exchange. This separation aims to sharpen focus on high-margin growth markets and is expected to enhance Medtronic’s overall margins and profitability.
Guidance for Fiscal Year 2026: The company anticipates approximately 5% organic revenue growth for FY26, with a projection of EPS growth of around 4%, excluding tariff impacts. This reflects ongoing confidence in key growth areas but factors in potential external challenges.
Exclusive for Stockcircle Pro members
Sign up
$119.24
39.3% upside
Current Fair Value
39.3% upsideUndervalued by 39.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $106.43 Billion |
|---|---|
| Enterprise Value | $132.92 Billion |
| Dividend Yield | $2.8 (3.37430706194264%) |
| Earnings per Share | $2.77 |
| Beta | 0.83 |
| Outstanding Shares | 1,282,400,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 24.98 |
|---|---|
| PEG | -1179.4 |
| Price to Sales | 3.42 |
| Price to Book Ratio | 2.25 |
| Enterprise Value to Revenue | 4 |
| Enterprise Value to EBIT | 28.63 |
| Enterprise Value to Net Income | 31 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.56 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Medtronic Plc
CEO: Geoffrey Martha